RVU — Ryvu Therapeutics SA Income Statement
0.000.00%
Last trade - 00:00- PLN639.25m
- PLN597.89m
- PLN77.97m
Annual income statement for Ryvu Therapeutics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.7 | 11.2 | 38.9 | 46.9 | 78 |
| Cost of Revenue | |||||
| Gross Profit | 6.89 | -25.5 | -0.644 | 21 | 54.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 51.3 | 89.8 | 117 | 148 | 200 |
| Operating Profit | -35.7 | -78.6 | -78.4 | -101 | -122 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -30.6 | -79 | -79.2 | -92.1 | -111 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -31.7 | -79.1 | -83.8 | -92.1 | -111 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -31.7 | -79.1 | -83.8 | -92.1 | -111 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -31.7 | -79.1 | -83.8 | -92.1 | -111 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.89 | -4.31 | -4.61 | -4.02 | -4.82 |
| Dividends per Share |